UCLA

Santa Monica, California 90404

10 studies enrolling now · 34 studies all time

What they study most

Acute Coronary Syndrome, Adrenocortical Carcinoma (Part G), Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Solid Tumors (Part A/B/C/D), Breast Cancer, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, Colorectal Cancer (CRC), Colorectal Neoplasms, Diabetes Mellitus, Type 1

Studies at this site

• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma — Recruiting now
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Recruiting now
• Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA — Recruiting now
• Starting Technology in At Risk Type 1 Diabetes Study — Recruiting now
• Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors — Recruiting now
• Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors — Recruiting now
• A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors — Recruiting now
• This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors — Recruiting now
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) — Stopped early
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) — Completed
• Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) — Completed
• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma — Completed
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
• Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections — Completed
• LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC — Status unconfirmed
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma — Status unconfirmed
• A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria — Completed
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 — Status unconfirmed
• A Study of IGN002 for Refractory NHL — Withdrawn before enrolling
• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects — Stopped early
• Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial — NO_LONGER_AVAILABLE
• A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 — Withdrawn before enrolling
• Study of Pomaglumetad and Methamphetamine — Stopped early
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants — Completed
• Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation — Completed
• Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) — Stopped early
• A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) — Completed
• A Study of LY2875358 in Participants With Advanced Cancer — Completed